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Summary: High-dimensional biomarkers such as genomics are increasingly being measured in randomized clinical trials.
Consequently, there is a growing interest in developing methods that improve the power to detect biomarker-treatment
interactions. We adapt recently proposed two-stage interaction detecting procedures in the setting of randomized clinical
trials. We also propose a new stage 1 multivariate screening strategy using ridge regression to account for correlations among
biomarkers. For this multivariate screening, we prove the asymptotic between-stage independence, required for the family-wise
error rate control, under the biomarker-treatment independence. Simulation results show that in various scenarios, the ridge
regression screening procedure can provide substantially greater power than the traditional one-biomarker-at-a-time screening
procedure in highly correlated data. We also exemplify our approach in two real clinical trial data applications.
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1. Introduction
Recent developments in medicine have seen a shift toward
targeted therapeutics (Collins and Varmus, 2015). It has
been shown that individual variability can often contribute to
differences in response to the same treatment (Khoury et al.,
2012). For example, a strong association of carbamazepine-
induced Stevens-Johnsons syndrome and the human leuko-
cyte antigen-B (HLA-B)*1502 allele was reported (Lochar-
ernkul et al., 2011). Another example is the Class II allele
HLA-DRB1*07:01 that has been associated with lapatinib-
induced liver injury (Parham et al., 2016). Detecting such in-
teractions between biomarkers and treatments in randomized
clinical trials is of growing interest.
Discovering biomarker-treatment interactions helps iden-
tify baseline predictive biomarkers in clinical trials (Robert
et al., 2014): biomarkers which influence treatment efficacy
can be used to find the subgroup of patients who are most
likely to benefit from the new treatment, as well as being
used to predict subgroup treatment effects (Wang and Dai,
2016). Consequently, new adaptive design approaches can be
used in settings where there are genetically-driven subgroups
to improve efficiency (Wason et al., 2015). Furthermore, the
discovery of novel biomarker-treatment interactions may re-
sult in the identification of new disease susceptibility loci,
providing insights into the biology of diseases. Such outcomes
are very much aligned with the goals of precision medicine:
to enable the provision of “the right drug at the right dose to
the right patient” (Collins and Varmus, 2015).
Detecting biomarker-treatment interactions in large-scale
studies of human populations is a non-trivial task, which faces
several challenging problems (McAllister et al., 2017). Tra-
ditional interaction analysis, using regression models to test
biomarker-treatment interactions one biomarker at a time,
may suffer from poor power when there is a large multiple
testing burden, for example when performing such analysis on
a genome-wide scale for genetic biomarkers. Standard geno-
typing microarrays measure half a million or more variants
and, when combined with whole genome imputation, can lead
to millions of biomarkers to consider. Another type of omics,
metabolomics - the measurement of metabolite concentrations
in the body - may have a more direct effect on drug efficacy
and is also becoming increasingly widely assayed.
In the context of gene-environment interaction studies,
there is now a significant literature of statistical methods,
which exploit aspects of the study design to improve power
thus mitigating the multiple testing burden. These include
case-only tests (Piegorsch et al., 1994), empirical Bayes
(Mukherjee and Chatterjee, 2008), Bayesian model averag-
ing (Li and Conti, 2008), and two-stage tests with different
screening procedures (Kooperberg and LeBlanc, 2008; Mur-
cray et al., 2008; Hsu et al., 2012; Gauderman et al., 2013;
Wason and Dudbridge, 2012). To alleviate the multiple testing
burden, two-stage methods use independent information from
the data to perform a screening test to select a subset of
genetic biomarkers, and then only test interactions within this
reduced set. Since there is a clear analogy to gene-environment
interaction problems, in this paper, we will examine how
existing gene-environment interaction testing methods may
be modified so that they are transferable to the biomarker-
treatment setting. Another significant drawback of the tradi-
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tional approach testing each biomarker one at a time is that
it fails to model correlations between biomarkers. We also
propose a novel screening test in two-stage approaches de-
tecting biomarker-treatment interactions, which utilizes ridge
regression to model correlated high-dimensional data. We
prove this new two-stage method is able to preserve the
overall family-wise error rate given independence between the
treatment and biomarkers. Furthermore, it is shown by sim-
ulations and real data applications that the new method can
provide better performance than traditional one-biomarker-
at-a-time approaches for correlated biomarkers. In the generic
context of variable selection, screening strategies have been
explored to focus algorithms on a reduced search space (Fan
and Lv, 2008; Wang and Leng, 2016). In this work, we explore
the use of variable pre-screening specifically to help identify
interactions.
2. Methods
2.1 Standard Single-Step One-Biomarker-at-a-Time
Interaction Tests
In the context of randomized clinical trials, one can test each
biomarker in turn for a biomarker-treatment interaction using
the following generalized linear model
G{E(Yi | Xij , Ti)} = β0j + βXjXij + βTTi
+βXj×TXij × Ti (1)
with Yi denoting the response outcome, Ti the binary
treatment-control indicator, and Xi1, . . . , Xim representing m
biomarkers, for the ith patient. G is a canonical link function.
The null hypothesis βXj×T = 0 could be tested for each
j = 1, . . . ,m, e.g. using a Wald test with the Bonferroni
correction applied to preserve the family-wise error rate (the
probability of at least one type I error).
The number of biomarkers m to be considered is potentially
large. Given the desired overall family-wise error rate α,
a Bonferroni correction (Dunn, 1961) requires an adjusted
significance level for each individual test to be α/m. Al-
though the Bonferroni correction is typically used for its
simplicity and flexibility, with regard to our interest in high-
dimensional interaction testing it is worth exploring whether
other procedures are able to provide improved efficiency. In
the supplementary material, we demonstrate theoretically
some alternative family-wise error rate controlling methods
can only provide a small improvement across the settings we
consider in this paper: when m is large and only a small subset
of biomarkers have true interactions with treatment. {Sidak
correction (Sidak, 1967), Holm-Bonferroni procedure (Holm,
1979) and Hochberg procedure (Hochberg, 1988)}
2.2 Two-Stage Interaction Tests with Some Existing
Screening Methods
Two-stage approaches use a screening test as a filtering stage
(stage 1) to select a subset of biomarkers, and then in stage
2, only test interactions within the reduced set of biomarkers
(a smaller m in the Bonferroni Correction results in a less
stringent significance level used in each single test), thus
increasing power. To preserve the overall family-wise error
rate, two-stage approaches rely on the stage 1 screening tests
being independent of the final stage 2 tests. More detail on
how this is proved follows.
A common stage 1 screening test used in two-stage inter-
action testing is a marginal association test (Kooperberg and
LeBlanc, 2008). Considering this type of screening test in the
clinical trial setting, the marginal effect of a biomarker on the
outcome can be measured in a regression model of the form
G{E(Yi | Xij)} = δ0j + δXjXij (2)
The screening procedure is conducted by testing the null
hypothesis δXj = 0 for j = 1, . . . ,m, with a pre-specified
significance level α1 ∈ (0, 1). In stage 2, one then tests interac-
tions using the one-biomarker-at-a-time model (1) within the
set of biomarkers selected at stage 1. Another way to utilize
stage 1 information is to test all m biomarkers in stage 2
using weighted significance levels, that add up to the targeted
error rate α, based on ordered biomarkers from stage 1. One
possible weighting scheme (Ionita-Laza et al., 2007) is: the B
most significant biomarkers, i.e. with lowest p-values in stage
1, are compared with an adjusted significance level (α/2)/B,
the next 2B biomarkers are compared with (α/4)/(2B), ...,
the next 2kB biomarkers are compared with (α/2k+1)/(2kB),
and so on.
The motivation of conducting marginal association tests
to screen for candidate interaction tests is that we expect a
biomarker that has an interaction with the treatment for the
disease will also show some level of marginal association with
the response. However, it is also possible that the biomarker’s
main association with response and the interaction effect
may be in opposite directions, such that the overall marginal
effect cancels out. When this is the case a marginal screening
strategy would fail due to the first stage test statistic having
low power.
To preserve the overall family-wise error rate, a key require-
ment to apply the two-stage approach is the independence
between stage 1 and 2 tests. Both Murcray et al. (2008)
and Dai et al. (2012) proved that: with stage 1 and 2 test
statistics being asymptotically independent and m∗ defined as
the number of stage 1 selected biomarkers, using a Bonferroni
adjusted significance level α = α/m∗ at stage 2 to test
interactions within the reduced set is sufficient to preserve
the overall family-wise error rate of the two-stage procedure
under α.
In the context of gene-environment interaction studies, an
alternative type of screening is testing the correlation between
a gene and the environmental factor (Murcray et al., 2008).
However, such a screening procedure is not generally applica-
ble to finding biomarker-treatment interactions in randomized
clinical trials. We make this argument and also discuss the
applicability of other related proposals more formally in the
supplementary material.
2.3 New Stage 1 Sparse Regression Screening Procedure
Accounting for Biomarker-Biomarker Correlations
One significant drawback of existing two-stage interaction
testing procedures is that biomarkers are only tested one
at a time. This ignores correlations between the biomarkers.
In a high-dimensional, low-sample-size data set, a traditional
ordinary least squares multivariate regression analysis testing
each predictor, while accounting for correlations with the
Two-Stage Sparse Regression Screening 3
other predictors, is not feasible. Therefore we considered
modern sparse regression methods to model correlated high-
dimensional data. These techniques have improved the de-
velopment of risk predictors from high-dimensional genomic
information (Wu et al., 2009; Lunn et al., 2006; Newcombe
et al., 2017).
We propose a new stage 1 multivariate screening test of
the following form to account for biomarker-biomarker corre-
lations
G{E(Yi | Xi1, . . . , Xim)} = δ0 + δTTi +
m∑
j=1
δXjXij (3)
This multivariate version of the marginal association screen-
ing test also includes the treatment main effect term. This
is necessary to preserve the independence between stage 1
screening and stage 2 interaction tests as described later.
To fit this multivariate model, we use ridge regression,
which applies regularization to avoid overfitting in high-
dimensional low-sample-size problems. Typically, the objec-
tive of ridge regression is to minimize a loss function Ln along
with an L2 regularization term:
Ln(δ) + λn||δ||22
where ||δ||22 = δ2T +
∑m
j=1 δ
2
Xj
. Ridge shrinks all the estimated
coefficients towards zero, but will not set them exactly to zero.
For use in a two-stage interaction testing strategy, we pro-
pose ordering the biomarkers based on the ridge coefficients
obtained from stage 1, and then use the resulting ranking
to determine varying significance thresholds across buckets
of markers during stage 2 one-at-a-time interaction tests
according to the weighting scheme described in Section 2.2.
Fitting a ridge model can be efficiently done through the
pathwise coordinate descent method (Friedman et al., 2010),
and the optimal value of the regularization parameter λn can
be chosen using cross-validation.
2.4 Proof of Independence between Stage 1 Sparse Regression
Screening and Stage 2 Standard Interaction Tests
In this section, we show that independence between stage 1
and stage 2 test statistics holds for stage 1 ridge regression
screening tests.
For the ith subject, let Yi denote the outcome variable,
Xi = (Ti, Xi1, . . . , Xim)
T be a vector of the binary treatment-
control indicator and m biomarkers. Consider the proposed
stage 1 marginal association screening test based on the
multivariate model of the form
G{E(Yi |Xi)} = XTi δ
where δ = (δT , δX1 , . . . , δXm)
T . The model underlying the
stage 2 standard one-biomarker-at-a-time interaction test is
of the form
G{E(Yi | V ij)} = V Tijβj (j = 1, . . . ,m)
where V ij = (Xij , Ti, XijTi)
T and βj = (βXj , βTj , βXj×T )
T .
The above forms ignore intercepts without loss of generality.
We first show the between-stage asymptotic independence
for the stage 1 multivariate regression marginal association
estimator without regularization.
Theorem 1: For any j = 1, . . . ,m, if Xij is independent
of Ti, and, E(Ti) = 0 or E(Xij) = 0 (i.e. Ti or Xij is centered
around 0), then under the null hypothesis βXj×T = 0,
cov(n1/2(δˆ0Xj − δXj ), n1/2(βˆXj×T − βXj×T ))→ 0
in probability, where δˆ0Xj and βˆXj×T are the maximum like-
lihood estimators for unknown parameters δXj and βXj×T
respectively without regularization (i.e. λn = 0).
The proof is provided in the appendix. Previous works
(Murcray et al., 2008; Dai et al., 2012) have demonstrated
the stage 1 univariate marginal association screening tests are
independent with the stage 2 one-biomarker-at-a-time inter-
action tests. Theorem 1 extends this to show independence
still holds when stage 1 tests are extended to a multivariate
regression. Our proof relies on: 1) the inclusion of the treat-
ment main effect in the multivariate regression of the form
(3); 2) an assumption of independence between the treatment
assignment and biomarker values, which is valid in the context
of a randomized clinical trial.
Next we establish the asymptotically linear form of the
ridge estimator.
Lemma 1: Under standard regularity conditions (Van der
Vaart, 2000, p. 51-52) and if λn = O(n
1/2), i.e.
limn→∞ λn/n1/2 = λ0 > 0, then
n1/2(δˆ
λ − δ)→ N (−2λ0Σ−1δ, σ2Σ−1)
in distribution, where δˆ
λ
is the ridge estimator, N is a normal
distribution, σ and Σ are a constant and an invertible constant
matrix.
Based on the asymptotic distributions derived in Lemma 1
and Theorem 1, we are able to prove the asymptotic in-
dependence between the stage 1 ridge marginal association
screening estimator and the stage 2 one-at-a-time interaction
estimator in the following corollary.
Corollary 1: For any j = 1, . . . ,m, if Xij is indepen-
dent of Ti, and, E(Ti) = 0 or E(Xij) = 0 (i.e. Ti or Xij is
centered around 0), then under the null hypothesis βXj×T = 0,
cov(n1/2(δˆλXj − δXj ), n1/2(βˆXj×T − βXj×T ))→ 0
in probability, where δˆλXj is the maximum likelihood estimator
with the ridge penalty.
Proofs of Lemma 1 and Corollary 1 are given in the supple-
mentary material.
3. Results
3.1 Simulation Study
To evaluate performance of our proposed biomarker-
treatment interaction testing procedure described above, we
generated simulated data sets, each having m = 1, 000
biomarkers. Data were simulated under the model Yi =
β0 + βTTi +
∑m
j=1(βXjXij + βXj×TXij × Ti) + εi, where
the treatment main effect was set to βT = 0.5 and the
intercept β0 = 0. We partitioned the 1, 000 biomarkers into
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50 clusters of correlated biomarkers, containing 20 biomarkers
each. We denote the clusters C1 = {X1, . . . , X20}, C2 =
{X21, . . . , X40}, and so on. One biomarker in the first cluster
was ascribed a main effect and an interaction effect, i.e.
βX1 = 0.5 and βX1×T = 1. Four other biomarkers in four
other different clusters were ascribed main effects on the trait
without interactions, i.e. βX21 = βX41 = βX61 = βX81 =
1.5. All other biomarkers do not have direct effects on the
outcome. Each biomarker Xj was generated from a standard
normal distribution N (0, 1) and the binary treatment assign-
ment was drawn from a Bernoulli(0.5) distribution, while
εi was generated from a normal distribution with standard
deviance 5. We consider two types of correlation patterns
among biomarkers: 1) The 20 biomarkers within each cluster
are correlated with each other (ρ = 0.6), but there are no
correlations between biomarkers in different clusters; 2) All
biomarkers are independent of one another (ρ = 0). For
each scenario, 1, 000 replicate data sets were generated to
estimate power and family-wise error rates. Power is defined
according to the idea of “cluster discoveries” in Brzyski
et al. (2017) as pr(reject at least one Hj0 for any Xj ∈ Ci |
at least one Hk1 is true for any Xk ∈ Ci), where Hj0 is the
null hypothesis for Xj and H
k
1 is the alternative hypothesis
for Xk.
Four different screening procedures are compared: 1) “Uni-
variate screening (threshold)”: A selection of biomarkers to
take forward to stage 2 is based on significance in a regression
of response on the biomarkers one at a time, of the form (2).
A significance level α1 = 0.05 is used without adjustment
for each stage 1 biomarker test. 2) “Univariate screening
(rank)”: All biomarkers are taken forward to stage 2, and
the stage 1 p-value ranking is used to conduct a stage 2
weighted hypothesis test described in Section 2.2 with B = 5
{a number recommended by Gauderman et al. (2013)}. 3)
“Ridge screening (rank)”: Ridge regression is used to estimate
marginal effects at stage 1. Then all biomarkers are ordered
based on these stage 1 coefficients and the rank will be used
by the stage 2 weighted hypothesis test with B = 5. The
optimal λn is chosen based on 5-fold cross-validation errors.
The R package glmnet (Friedman et al., 2010) was used. 4)
“No screening”: A standard single-step interaction test of the
form (1), targeting an overall family-wise error rate α = 0.05,
is performed as a baseline comparator and also as the stage 2
test for all the three two-stage approaches described above.
In Fig. 1(a), with highly correlated biomarkers, the pro-
posed ridge regression screening procedure demonstrated sub-
stantially higher power than the univariate screening proce-
dures, showing a clear benefit of accounting for correlations
between the biomarkers at stage 1. In Fig. 1(b), with in-
dependent biomarkers, where the multivariate regression is
not required for unbiased effect estimation, the univariate
screening and the ridge screening procedures using weighted
hypothesis tests perform similarly. All three two-stage tests
outperformed the single-step interaction test by providing
better power at the same family-wise error rate level whether
biomarkers are correlated or independent.
In Fig. 1(c), we simulated scenarios with one biomarker
having an interaction, no correlations among the biomarkers,
and changed only the main effect of the interacting biomarker
βX1 , i.e. main effects of the other four biomarkers were the
Figure 1. Comparison of two-stage interaction tests with
different screening testing procedures. Four were compared:
univariate screening (threshold) (long dashes), univariate
screening (rank) (short dashes), ridge screening (rank) (dot-
dash), and no screening (solid). The four panels represent:
(a) highly correlated biomarkers (ρ = 0.6), (b) independent
biomarkers (ρ = 0), (c) independent biomarkers (ρ = 0),
changing the main effect of the interacting biomarker βX1 ,
(d) highly correlated biomarkers (ρ = 0.6), changing the
standard deviance of the normal distribution from which εi
was drawn and consequently the variance explained in the
outcome. (This figure appears in color in the electronic version
of this article.)
same as the previous scenario. The sample size was fixed at
1, 500. Fig. 1(c) reveals that there will be some special cases,
in which the main and interaction effect parameters are in
opposite directions such that they cancel out, where all two-
stage approaches give lower power than a standard single-step
interaction test.
In Fig. 1(d), we compared power of the different screening
strategies while varying the proportion of explained variation
by the true model. Specifically, we changed the standard
deviance of the normal distribution from which εi was drawn
from. For this exploration, biomarkers were set to be cor-
related at 0.6. Fig. 1(d) shows that when the true model
explains either a low or high proportion of the variance, all the
methods tend to perform similarly to each other. In the wide
spectrum between the two extremes, the comparison is rather
consistent: the sparse regression screening strategy performs
best, followed by the two univariate screening procedures,
with the single-step interaction test always resulting in the
lowest power.
In the supplementary material, we summarize family-wise
error rates in different scenarios, which shows no inflation
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for all the screening procedures. Additionally, we provide
simulation results of scenarios in which we changed the inter-
action effect of the interacting biomarker and the correlation
between biomarkers. Relative patterns of performance among
the screening strategies were consistent with the results de-
scribed above, demonstrating the robustness of our method
and findings.
3.2 Data Applications
In addition to validating our methods through simulations,
we exemplified our approaches in two real data applications.
Our first application was to data from the randomized con-
trolled trial START (Fonagy et al., 2018), which is composed
of 684 participants aged from 11 to 17 with antisocial behav-
ior, half of whom were treated with management as usual (the
control arm) and the rest were treated with multisystemic
therapy followed by management as usual (the treatment
arm). We used a secondary outcome of this trial, the 18
months’ follow-up outcome from Inventory of Callous and
Unemotional Traits, as the continuous outcome and applied
our interaction testing procedures to detect covariates having
interactions with the treatment. We excluded covariates with
more than 10% missing data and used mean imputation to
replace missing values for covariates with less than 10% miss-
ing data. As a result, 75 covariates (demographics, baseline
questionnaires, offending history and psychiatric diagnoses)
were included in the analysis. Correlation among these co-
variates is generally low (a correlation plot is provided in the
supplementary material).
We performed all the four screening procedures described
in the previous section with a significance level of α = 0.05
and did not find any significant interactions. Table 1 lists the
top covariates output by the univariate screening and ridge
screening procedures. It is shown that the selected covariates
from these two procedures are similar in this data set where
covariates have low correlation.
In the second application with binary outcomes, we applied
our approaches to detect biomarkers of steroid response in
the treatment of alcoholic hepatitis (STOPAH trial) (Thursz
et al., 2015). The dataset consists of 1, 068 subjects. In this
2 × 2 factorial trial, each patient was randomized twice:
the first randomization was between with and without pred-
nisolone (534 : 534) and the second was between with and
without pentoxifylline (537 : 531). 28-day mortality was used
as the binary response endpoint. We excluded biomarkers
with more than 10% missing data and used mean imputation
to replace missing values for biomarkers with less than 10%
missing data. As a result, 40 covariates (a small number
of which were demographic variables) were included in the
analysis for detecting interaction with treatment. There exists
substantial correlation among these biomarkers (a correlation
plot is provided in the supplementary material).
All the four methods described in the previous section with
a significance level of α = 0.05 did not find any significant
biomarker-treatment interactions. Table 1 summarizes the
top biomarkers from different marginal screening procedures:
The results are quite different between the sparse regression
screening and the univariate screening, likely owing to the
high correlation among the biomarkers.
In addition, we examined the empirical correlation between
stage 1 ridge screening and stage 2 interaction test statistics
applied in the above two real data sets. Table 2 summarizes
results from Pearson correlation tests, which shows that the
empirical correlation between stages is close to zero and in all
cases the 95% confidence interval contains zero as expected.
4. Discussion
We propose, for the first time with formal justification, the
use of sparse ridge regression in a two-stage interaction test-
ing framework for identifying biomarker signatures of treat-
ment efficacy in randomized clinical trials. Interaction testing
frameworks which are designed to scale to large numbers
of covariates will become ever more important as -omics
technologies continue to drop in price and become routinely
measured in clinical trials.
It is known that ridge regression has a tendency to average
effects across strongly correlated covariates. This phenomenon
is not desirable for a screening strategy since it could inflate
the number of non-interacting biomarkers being put forward
to stage 2. Thus, lasso as an alternative sparse regression
model which does not exhibit this effect averaging behavior
may be expected to perform better. However, as lasso uses a
L1 penalty which is not a smooth function, it is challenging to
prove it meets the between-stage independence requirement
to preserve the overall family-wise error rate in two-stage
approaches using current asymptotic theory. Other formula-
tions of sparse regression methods, e.g. group lasso (Yuan and
Lin, 2006), elastic net (Zou and Hastie, 2005), and Bayesian
variable selection (O’Hara et al., 2009), that could be used at
stage 1 or 2 are also worth exploring in future research.
We also showed that there exist special cases where our
proposed two-stage screening strategy offers no benefit, e.g.
the case when the main effect of a biomarker and its in-
teraction effect with the treatment to the response are in
opposite directions, such that the marginal effect cancels out.
We suggest exploring the weighting scheme thus changing how
much stage 1 information to be used in the following stage 2
tests as a future topic for investigation. Another technical
caveat was shown by Sun et al. (2018) that, for logistic
regression, the interaction estimator under treatment mis-
specification can be biased when the biomarker is associated
either indirectly or directly with the outcome. This is a generic
issue to interaction modeling using logistic regression, but
could manifest in our framework as an elevated family-wise
error rate at stage 2 one-biomarker-a-time tests. Therefore, we
highlight that, currently, our theoretical work only guarantees
family-wise error rate control when using linear regression.
The extent to which this bias might inflate family-wise error
rates when applying our framework using logistic regression,
and potential corrections, will be the topic of future work. We
note, however, that since no strong evidence of interactions
was found in our STOPAH case study, this bias is not a
concern there - specifically the bias will generally manifest
as false positives as opposed to false negatives.
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Table 1
Top covariates from different stage 1 marginal screening
procedures
START trial
Univariate screening Ridge screening
1 Total Inventory of Callous
and Unemotional Traits
Total Inventory of Callous
and Unemotional Traits
2 Total Antisocial Beliefs
and Attitudes Scale
Total Antisocial Beliefs
and Attitudes Scale
3 Strengths & Difficulties
Conduct Problems Score
Strengths & Difficulties
Conduct Problems Score
4 Strengths & Difficulties
ProSocial Behaviour Score
Strengths & Difficulties
ProSocial Behaviour Score
5 Strengths & Difficulties
Hyperactivity Score
Strengths & Difficulties
Hyperactivity Score
6 Volume of self reported
delinquency excluding vi-
olence towards siblings
Volume of self reported
delinquency excluding vi-
olence towards siblings
7 Strengths & Difficulties
Total Difficulties Score
Strengths & Difficulties
Total Difficulties Score
8 IQ IQ
9 Variety of self reported
delinquency excluding vi-
olence towards siblings
Parental reported total In-
ventory of Callous and
Unemotional Traits
10 Parent reported Strengths
& Difficulties Conduct
Problems Score
Alabama Positive
Parental Involvement
Score
STOPAH trial (pentoxifylline)
Univariate screening Ridge screening
1 Max GAHS Age
2 MELD Max GAHS
3 GAHS MELD
4 UNOS MELD UNOS MELD
5 Max GAHS - Categorical GAHS
6 GAHS - Categorical WHO Performance Status
- Worst
7 Creatinine Hepatic Encephalopathy
8 Discriminant Function Urea
9 WHO Performance Status
- Worst
Hepatic Encephalopathy -
Worst
10 Urea WHO Performance Status
STOPAH trial (prednisolone)
Univariate screening Ridge screening
1 Max GAHS MELD
2 MELD Max GAHS
3 GAHS UNOS MELD
4 UNOS MELD GAHS
5 Max GAHS - Categorical Age
6 GAHS - Categorical Creatinine
7 Creatinine Urea
8 Discriminant Function WHO Performance Status
- Worst
9 WHO Performance Status
- Worst
Hepatic Encephalopathy
10 Urea Hepatic Encephalopathy -
Worst
Table 2
Empirical correlation between stage 1 ridge screening and
stage 2 interaction test statistics
START STOPAH
(pentox-
ifylline)
STOPAH
(pred-
nisolone)
Estimate 0.044 0.104 0.008
P value 0.711 0.523 0.960
95% confidence interval (-0.188,
0.271)
(-0.214,
0.402)
(-0.304,
0.319)
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Appendix
Proof of Theorem 1
Based on the unified approach to prove between-stage asymp-
totic independence by Dai et al. (2012), we need to evaluate
the covariance matrix A−11 BA
−1
2 , where
A1 = E[(XiX
T
i ){Yi − E(Yi |Xi)}2]
B = E[(XiV
T
ij){Yi − E(Yi |Xi)}{Yi − E(Yi | V ij)}]
A2 = E[(V ijV
T
ij){Yi − E(Yi | V ij)}2]
We simplify the expression of B as
B = E[(XiV
T
ij){Y 2i − YiE(Yi |Xi)− YiE(Yi | V ij)
+E(Yi |Xi)E(Yi | V ij)}]
= E[(XiV
T
ij)E{Y 2i − YiE(Yi |Xi)− YiE(Yi | V ij)
+E(Yi |Xi)E(Yi | V ij) |Xi}]
= E(XiV
T
ij)var(Yi |Xi)
which uses the law of iterated expectations, the fact that
Xi includes V ij under the null hypothesis βXj×T = 0, and
assumes the homogeneity of variance, i.e. var(Yi | Xi) is a
constant.
Similarly, we have A1 = E(XiX
T
i )var(Yi |Xi) and A2 =
E(V ijV
T
ij)var(Yi | V ij). Thus,
A−11 BA
−1
2 ∝ E(XiXTi )−1E(XiV Tij)E(V ijV Tij)−1
We consider the second and the third terms
E(XiV
T
ij)
(m+1)×3
=

E(TiXij) E(T
2
i ) E(T
2
i Xij)
E(Xi1Xij) E(TiXi1) E(TiXi1Xij)
...
...
...
E(XimXij) E(TiXim) E(TiXimXij)

E(V ijV
T
ij)
−1
3×3
=
 E(X2ij) E(TiXij) E(TiX2ij)E(TiXij) E(T 2i ) E(T 2i Xij)
E(TiX
2
ij) E(T
2
i Xij) E(T
2
i X
2
ij)
−1
=
1
det{E(V ijV Tij)}
·
 · · E(TiXij)E(T 2i Xij)− E(T 2i )E(TiX2ij)· · E(TiXij)E(TiX2ij)− E(X2ij)E(T 2i Xij)
· · E(X2ij)E(T 2i )− E(TiXij)2

Thus, for the (m+ 1)× 3 matrix E(XiV Tij)E(V ijV Tij)−1,
the (k + 1)th element (k = 1, . . . ,m) of the last column can
be computed by
1
det{E(V ijV Tij)}
(
E(XikXij), E(TiXik), E(TiXikXij)
)
·
 E(TiXij)E(T 2i Xij)− E(T 2i )E(TiX2ij)E(TiXij)E(TiX2ij)− E(X2ij)E(T 2i Xij)
E(X2ij)E(T
2
i )− E(TiXij)2

=
1
det{E(V ijV Tij)}
·E(Ti)var(Ti)E(Xij){E(XikXij)E(Xij)− E(Xik)E(X2ij)}
= 0
which uses the independence between Ti and Xij , and the
assumption E(Ti) = 0 or E(Xij) = 0. Similarly, the first
element of the last column is also zero.
Premultiplying E(XiV
T
ij)E(V ijV
T
ij)
−1 by E(XiXTi )
−1
completes the covariance matrix, the last column of which are
all zeros. Thus, for any j = 1, . . . ,m, we have cov(n1/2(δˆ0Xj −
δXj ), n
1/2(βˆXj×T − βXj×T ))→ 0 in probability.
